Biotech Values

[puravida]

ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company

The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the transaction, on a fully diluted basis, ImmunityBio shareholders will own approximately 72% of the combined company and NantKwest shareholders will own approximately 28% of the combined company, on a fully diluted basis.




https://ir.nantkwest.com/news-releases/news-release-details/immunitybio-and-nantkwest-merge-creating-leading-immunotherapy?field_nir_news_date_value[min]=